Abstract: Objective To analyze the clinical efficacy of tenofovir fumarate in the treatment of chronic hepatitis B and understand its impact on portal vein hemodynamics. Methods 103 patients with chronic hepatitis B were selected and divided into two groups based on different treatment methods. The tenofovir fumarate group had 52 cases and the tenofovir tablets group had 51 cases. We compared the general information, laboratory indicators, virological indicators, and portal vein hemodynamic indicators of the patients in two groups before and after treatment. Results The laboratory indicators of both groups were significantly improved, and the HBV DNA load of Tenofovir fumarate group was (0.72±0.05), which was lower than (0.88±0.04) that of the Tenofovir tablet group, with statistical significance (P<0.05). In tenofovir fumarate group, the AST was (28.64±5.49) U/L, ALT was (39.23±4.72) U/L, TB was (10.59±1.03) mol/L, which were lower than (32.08±5.04) U/L, (43.54±5.03) U/L and (12.52±1.12) mol/L in Tenofovir tablet group, respectively, with statistical significance (P<0.05). The velocity of blood portal vein (VPV) of Tenofovir fumarate group was (15.09±1.75) cm/s, which was higher than (14.37±1.88) cm/s that of Tenofovir tablet group, while the quantity of portal venous (Qpv) and diameter of portal vein (DPV) of Tenofovir fumarate group were (948.53±92.34) ml/min and (0.98±0.03) cm respectively. Quantity of splenic venous (Qsv) was (456.24±19.82) ml/min, liver hardness was (8.57±1.22) kPa, which were lower than (1006.45±90.76) ml/min, (1.12±0.05) cm, (599.58±22.48) ml/min and (9.83±1.47) kPa in Tenofovir tablet group, respectively, with statistical significance (P<0.05). Conclusion The clinical efficacy of tenofovir fumarate in the treatment of chronic hepatitis B is good, and it has better advantages in portal vein hemodynamics, which can be recommended for clinical use.

Key words: Tenofovir Fumarate Ester, Chronic hepatitis B, Portal vein, Hemodynamics